1 Change in central subfield thickness was the
primary outcome measure.
2 .0% without antiglycemic medication) was the
primary outcome measure.
3 Visual acuity at 2 years was the
primary outcome measure.
4 27-hydroxycholesterol levels in serum as the
primary outcome measure.
5 perator TNSS (the sum of 13 ratings) was the
primary outcome measure.
6 ed by the presence or absence of SCT was the
primary outcome measure.
7 r cingulate and dorsolateral regions-was the
primary outcome measure.
8 ion site, diagnosis method and criteria, and
primary outcome measure.
9 Time to diagnosis of AF was the
primary outcome measure.
10 gdala lesions reduced loss adaptation in the
primary outcome measure.
11 n should use active movement and function as
primary outcome measures.
12 home, and time spent away from home were the
primary outcome measures.
13 ared with those who received placebo on both
primary outcome measures.
14 mily-based CBT was superior to FB-RT on both
primary outcome measures.
15 rking memory, and processing speed) were the
primary outcome measures.
16 atients completed the study duration for the
primary outcome measure (
43 were women [41%]).
17 not reduce symptoms of nausea, based on the
primary outcome measure (
46% reduction in the VAS score
18 actions between group differences for either
primary outcome measure after adjusting for additional c
19 The
primary outcome, measured after listening to the entire
20 ne IOP < 25 mm Hg in both studies (ROCKET-2,
primary outcome measure and population, ROCKET-1, post h
21 and in vivo assays using angiogenesis as the
primary outcome measure and the mechanisms through which
22 e upper limbs by Fugl-Meyer Assessment (FMA;
primary outcome measure)
and analysis of oscillatory act
23 Asberg Depression Rating Scale score (MADRS;
primary outcome measure)
and Clinical Global Impressions
24 Eye pain intensity was the
primary outcome measure,
and interference with quality o
25 total of 779 patients provided data for the
primary outcome measure at baseline and at least 1 follo
26 mg, at baseline and every 4 weeks, with the
primary outcome measured at 6 months.
27 f participants enrolled, 139 (94%) completed
primary outcome measures at 3 months and 133 (90%) compl
28 A total of 160 participants (98%) completed
primary outcome measures at 6 months.
29 The
primary outcome, measured at the end of the school term,
30 ow-up was for 2 years after the surgery; the
primary outcomes, measured at 1 year and 2 years, were p
31 Primary outcomes, measured at 6 months after enrollment,
32 ntervention did not significantly affect the
primary outcome measure between December, 2014, and Marc
33 The
primary outcome, measured by the trial statistician who
34 from start of treatment to "presumed cure" (
primary outcome measure,
defined as a closed epithelial
35 group acts as a test-retest control for the
primary outcome measure examined in this study, change i
36 nalysis, change in bone fill was used as the
primary outcome measure,
except in cases in which this i
37 However, the
primary outcome measure failed to capture differences in
38 Primary outcome measures focused on assessment of malign
39 Physical function was found to be a suitable
primary outcome measure for a future trial; adjusted mea
40 The
primary outcome measure for feasibility was patient-repo
41 the percentage change from screening as the
primary outcome measure for statistical analysis of chan
42 The
primary outcome measure for the case-control study was t
43 Assessing
primary outcome measures for groups that received tDCS a
44 The
primary outcome measures for the study were coverage of
45 Secondary outcomes were consistent with the
primary outcome measure in reflecting better outcomes as
46 The
primary outcome measure in this study was steroid-free r
47 mbulant patients with DMD; both of which are
primary outcome measures in clinical trials.
48 Primary outcome measures include change in hepatic injur
49 Primary outcome measures include rates of live births, e
50 Primary outcome measures included change in proteinuria
51 Primary outcome measures included quarterly inpatient ad
52 The
primary outcome measures included the subjective snoring
53 Primary outcome measures included: 1) radiographic bone
54 The
primary outcome measure is a change in body fat from bas
55 Our
primary outcome measure is a difference in mortality bet
56 The
primary outcome measure is the change in best-corrected
57 The
primary outcome measure is the cutoff point at or below
58 The
primary outcome measure is the rate of surgical failure,
59 Primary outcome measure is the total number of severe pr
60 mputed tomography angiography, we assessed 3
primary outcome measures:
left ventricular (LV) systolic
61 d value contingency management group met the
primary outcome measure (
odds ratio 12.1, 95% CI 3.7-39.
62 A baseline injection was given, with the
primary outcome measure of at least a 2-step reduction o
63 ly relevant reductions were achieved for the
primary outcome measure of daily summation operator TNSS
64 A sensitivity analysis utilizing the
primary outcome measure of survival to discharge or orga
65 The
primary outcome measure of the study was overall surviva
66 The
primary outcome measure of the trial was the macroscopic
67 The
primary outcome measures of interest were quantitative v
68 this cohort over a 7-year period, recording
primary outcome measures of occurrence of first seizure,
69 To determine
primary outcome measures of peak power and oxygen consum
70 For the
primary outcome, measures of risk discrimination showed
71 oup differences in the changes in any of the
primary outcome measures (
PWV changed by +9.5% and +6.0%
72 ements associated with CBT were found on the
primary outcome measures relating to quality of life (us
73 Although the
primary outcome measure result includes the prespecified
74 menstrual Tension Scale (PMTS) score was the
primary outcome measure (
score range, 0-36; 36 indicates
75 The rate of positive margins was the
primary outcome measure;
secondary outcome measures incl
76 No difference was observed on the study's
primary outcome measure,
the clinician-rated MADRS chang
77 Our
primary outcome measure,
the difference between predrug
78 difference from placebo was detected on the
primary outcome measure,
the parent-rated Aberrant Behav
79 hildren with ASD [as measured by the trial's
primary outcome measure,
the Social Responsiveness Scale
80 PRIMARY OUTCOME MEASURE:
Uncorrected (UCDVA) and best-co
81 Primary outcome measures varied across the trials analys
82 The change from baseline to month 24 on the
primary outcome measure was 0.18 for olesoxime and -1.82
83 Primary outcome measure was 14-day mortality.
84 The
primary outcome measure was 30-day ERI.
85 The
primary outcome measure was 30-day SSI.
86 The
primary outcome measure was 5-year overall survival.
87 The
primary outcome measure was 90-day mortality.
88 The
primary outcome measure was a composite endpoint of card
89 The
primary outcome measure was a composite of all-cause dea
90 The
primary outcome measure was a composite of catheter-rela
91 The
primary outcome measure was a composite of myocardial in
92 The
primary outcome measure was a delusion score derived fro
93 The
primary outcome measure was a difference in clinical dec
94 The
primary outcome measure was a three-level outcome - surv
95 The
primary outcome measure was adenosine diphosphate (ADP)-
96 The
primary outcome measure was advanced adenomatous polyps
97 The
primary outcome measure was agreement between catheteriz
98 The
primary outcome measure was all-cause mortality rate at
99 The
primary outcome measure was all-cause mortality within 3
100 Main Outcomes and Measures: The
primary outcome measure was all-cause mortality.
101 The
primary outcome measure was all-cause mortality.
102 Primary outcome measure was all-cause mortality.
103 ine deficiency has been completed in which a
primary outcome measure was an assessment of the neurobe
104 The
primary outcome measure was an increase in women publish
105 The
primary outcome measure was analysed using linear regres
106 The
primary outcome measure was anterior chamber cell grades
107 Primary outcome measure was awakening, defined as the ab
108 The
primary outcome measure was best-corrected visual acuity
109 The
primary outcome measure was change from baseline compare
110 The
primary outcome measure was change from baseline to day
111 The
primary outcome measure was change in antimicrobial pres
112 The
primary outcome measure was change in BMI over 5 years.
113 The
primary outcome measure was change in body mass index (B
114 The
primary outcome measure was change in depression severit
115 The
primary outcome measure was change in forced expiratory
116 Primary outcome measure was change in HbA1c level after
117 The
primary outcome measure was change in off time from base
118 The
primary outcome measure was change in peak oxygen consum
119 The
primary outcome measure was change in score on the Montg
120 The
primary outcome measure was change in serum zinc concent
121 The
primary outcome measure was change in sickness absence a
122 The
primary outcome measure was change in suicidal ideation,
123 The
primary outcome measure was child weight loss (body mass
124 The
primary outcome measure was clinical event rates, measur
125 The
primary outcome measure was clinical response, defined a
126 The
primary outcome measure was confirmed cancer that was mi
127 The
primary outcome measure was conversion from caries-free
128 The
primary outcome measure was conversion from caries-free
129 The
primary outcome measure was cortical thickness.
130 The
primary outcome measure was cumulative rates of melanoma
131 The
primary outcome measure was detection of asymptomatic tu
132 The
primary outcome measure was development of >/=1 SAE; sec
133 The
primary outcome measure was development of inhibitors (n
134 The
primary outcome measure was device retention at 24 and 6
135 Primary outcome measure was eradication of seeds and glo
136 The
primary outcome measure was event-free survival measured
137 The
primary outcome measure was failure of NOM.
138 The
primary outcome measure was flow disruptions, with treat
139 The
primary outcome measure was flow-mediated dilatation; se
140 The
primary outcome measure was graft failure-free survival;
141 Primary outcome measure was hazard ratio (HR) of failure
142 The
primary outcome measure was health-related quality of li
143 The
primary outcome measure was improvement in centrally sco
144 The
primary outcome measure was in-hospital mortality, and r
145 The
primary outcome measure was in-hospital mortality, and s
146 The
primary outcome measure was in-hospital mortality.
147 Primary outcome measure was incidence and severity of sy
148 The
primary outcome measure was incidence of new infections
149 Primary outcome measure was intraocular pressure (IOP) r
150 Primary outcome measure was intraocular pressure (IOP) r
151 The
primary outcome measure was late toxicity.
152 Primary outcome measure was mean change from baseline CS
153 The
primary outcome measure was mean change in letter score
154 The
primary outcome measure was median reaction time on the
155 The
primary outcome measure was methyl aminolevulinate-induc
156 Primary outcome measure was monthly use of CT pulmonary
157 The
primary outcome measure was net health benefit (NHB), wh
158 Our
primary outcome measure was overall firearm-related mort
159 The
primary outcome measure was overall survival (defined as
160 The
primary outcome measure was overall survival, and primar
161 The
primary outcome measure was overall survival.
162 The
primary outcome measure was overall survival.
163 The
primary outcome measure was overall survival.
164 The
primary outcome measure was overall survival; short-term
165 Our
primary outcome measure was parasite prevalence in evalu
166 Primary outcome measure was parent-reported Strength and
167 The
primary outcome measure was percentage of eyes with impr
168 Our
primary outcome measure was potential deceased organ don
169 The
primary outcome measure was prolonged validated abstinen
170 The median follow-up was 6.9 y, and the
primary outcome measure was prostate-cancer-specific mor
171 The
primary outcome measure was quality-adjusted life-years
172 The
primary outcome measure was reduction in child TSE.
173 The
primary outcome measure was reduction in hospitalization
174 The
primary outcome measure was remission, assessed with the
175 The
primary outcome measure was resolution of definite non-a
176 Primary outcome measure was resolution of macular edema
177 Our
primary outcome measure was response rate at the study e
178 The
primary outcome measure was response, defined as a 50% o
179 The
primary outcome measure was restoration of a completely
180 The
primary outcome measure was specific disease or diseases
181 The
primary outcome measure was speech comprehension score o
182 The
primary outcome measure was SSI score 24 hours after inf
183 The
primary outcome measure was stabilization of keratoconus
184 The
primary outcome measure was success rates after ALPI at
185 The
primary outcome measure was surgical success (intraocula
186 The
primary outcome measure was surgical success.
187 The
primary outcome measure was survival at hospital dischar
188 The
primary outcome measure was survival to hospital dischar
189 The
primary outcome measure was symptom counts assessed thro
190 The
primary outcome measure was the AAA expansion rate, dete
191 Measurements: The
primary outcome measure was the Alzheimer's Disease Coop
192 The
primary outcome measure was the Alzheimer's Disease Coop
193 The
primary outcome measure was the area under the curve (AU
194 The
primary outcome measure was the change in 6-minute walk
195 Primary outcome measure was the change in central macula
196 The
primary outcome measure was the change in DAS28-ESR betw
197 The
primary outcome measure was the change in IOP from basel
198 The
primary outcome measure was the change in the 17-item Ha
199 The
primary outcome measure was the change in the Epworth Sl
200 The
primary outcome measure was the change in the physical-c
201 The
primary outcome measure was the change in the preoperati
202 The
primary outcome measure was the Clinician-Administered P
203 The
primary outcome measure was the correlation between plas
204 The
primary outcome measure was the dermatological sum score
205 The
primary outcome measure was the detection of lesions by
206 The
primary outcome measure was the difference between group
207 Primary outcome measure was the difference in change in
208 The
primary outcome measure was the difference in disease se
209 Our
primary outcome measure was the direction and magnitude
210 Based on a previous report, the
primary outcome measure was the effect of intra-epoch ti
211 The
primary outcome measure was the frequency and nature of
212 The
primary outcome measure was the frequency of AEs.
213 The
primary outcome measure was the incidence of adverse eve
214 The
primary outcome measure was the length of attribution at
215 The
primary outcome measure was the negative predictive valu
216 Primary outcome measure was the neurologic outcome based
217 The
primary outcome measure was the number of RTIs not progr
218 The
primary outcome measure was the number of suicide attemp
219 The
primary outcome measure was the occurrence of any advers
220 The
primary outcome measure was the PANSS negative factor sc
221 The
primary outcome measure was the percentage of accuracy o
222 The
primary outcome measure was the percentage of families s
223 The
primary outcome measure was the persistence of pHPT.
224 The
primary outcome measure was the Positive and Negative Sy
225 The
primary outcome measure was the proportion of eyes that
226 In the follow-up study, the
primary outcome measure was the proportion of participan
227 Primary outcome measure was the proportion of patients w
228 The
primary outcome measure was the proportion of rA TTEs.
229 The
primary outcome measure was the rate of antibiotic items
230 The
primary outcome measure was the rate of first-attempt su
231 The
primary outcome measure was the rate of recurrent biliar
232 The
primary outcome measure was the Scale for the Assessment
233 The
primary outcome measure was the score on the Montgomery-
234 Main Outcomes and Measures: The
primary outcome measure was the sensitivity and specific
235 The
primary outcome measure was the shift in the degree of d
236 The
primary outcome measure was the shift in the degree of d
237 The
primary outcome measure was time from tracheostomy inser
238 The
primary outcome measure was to characterize the clinical
239 The
primary outcome measure was to determine the proportion
240 The
primary outcome measured was the postoperative early and
241 The
primary outcomes measure was the incidence of CRC and po
242 The
primary-outcome measure was analyzed with an ordinal met
243 with development of thoracic metastases, the
primary outcome measure,
was studied by using logistic r
244 The
primary outcome measures were abstinence from drugs and
245 Primary outcome measures were acceptance rates at US med
246 The
primary outcome measures were antipsychotic use, agitati
247 Primary outcome measures were assessed at 6 months and m
248 study is its open-label design, although the
primary outcome measures were assessed in a blinded mann
249 Primary outcome measures were changes from baseline in d
250 Intention-to-treat
primary outcome measures were changes in HDRS17 and GAF
251 The
primary outcome measures were clinical resolution of dia
252 Main Outcomes and Measures: The
primary outcome measures were clinicopathological charac
253 The
primary outcome measures were clinicopathological charac
254 Primary outcome measures were death-censored graft failu
255 The
primary outcome measures were depression (measured by th
256 The
primary outcome measures were diagnostic accuracy, sensi
257 Primary outcome measures were endothelial rejection-free
258 Primary outcome measures were errors during the real pro
259 Two composite
primary outcome measures were evaluated: (i) CVD events/
260 Primary outcome measures were final mean changes in BCVA
261 The
primary outcome measures were for insomnia, paranoia, an
262 The
primary outcome measures were IOP reduction and the succ
263 The
primary outcome measures were levels of plasma metabolit
264 Primary outcome measures were mean change in (1) tear os
265 Risk-adjusted
primary outcome measures were mean number of head CT sca
266 Primary outcome measures were midgestational indexes of
267 The
primary outcome measures were mortality from breast canc
268 The
primary outcome measures were overall mortality and canc
269 The
primary outcome measures were patients with repeated com
270 The
primary outcome measures were percentage representation
271 The
primary outcome measures were positive donor rim fungal
272 The
primary outcome measures were safety (the number, seriou
273 The
primary outcome measures were safety (the number, seriou
274 The
primary outcome measures were spiritual well-being and o
275 Primary outcome measures were technical performance as m
276 Primary outcome measures were the changes in ganglion ce
277 The
primary outcome measures were the Evaluation du Vecu de
278 The
primary outcome measures were the frequency of complete
279 Primary outcome measures were the mean and median CMS pa
280 The
primary outcome measures were the mean change in best co
281 The
primary outcome measures were the mean total Patient and
282 The
primary outcome measures were the postintervention chang
283 Primary outcome measures were the prevalence of diagnose
284 Primary outcome measures were the Rating for Premenstrua
285 The
primary outcome measures were the suicide items from cli
286 The
primary outcome measures were the treatment effect on en
287 Primary outcome measures were time to remission (with re
288 The
primary outcome measures were to evaluate the safety, ac
289 Main Outcomes and Measures: The
primary outcome measures were tumor characteristics, pro
290 The
primary outcome measures were weight and cardiorespirato
291 Primary outcome measures were: perinatal mortality, pret
292 Primary outcome measures were: time taken, path length,
293 The
primary outcomes measured were annual central venous cat
294 The
primary outcomes measured were numerical rating scale at
295 The
primary outcomes measured were the sensitivity and speci
296 HRs for OS (the
primary outcome measure)
were pooled to provide an aggre
297 Main Outcomes and Measures: HRs for OS (the
primary outcome measure)
were pooled to provide an aggre
298 emission at 12 months since baseline was the
primary outcome measure while the secondary outcome meas
299 0 [complete disability]) at 6 months was the
primary outcome measure,
with a minimal clinically impor
300 t trials employing EDSS change of 1.0 as the
primary outcome measure would be powered to detect a 20%